CombiMatrix Appoints Molecular Diagnostics Veteran Dirk van den Boom, Ph.D. to its Board of Directors
March 01 2017 - 6:00AM
CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular
diagnostics company specializing in DNA-based reproductive health
and pediatric testing services, announces that Dirk van den Boom,
Ph.D., has joined the Company’s Board of Directors, increasing
Board membership to six.
“Dirk is a recognized leader in the development
and commercialization of reproductive health diagnostics,” said R.
Judd Jessup, Chairman of CombiMatrix. “He brings a scientific
perspective to the board along with a wealth of executive-level and
strategic planning experience that will be invaluable as we build
on our established position in this market. Dirk also shares
our passion for providing high-quality test results that assist
physicians and their patients in family health and planning, making
him an ideal fit for our Board. We look forward to calling on
Dirk’s expertise and guidance, and we are delighted to welcome him
to our Company.”
Dr. van den Boom most recently served as
President, Chief Executive Officer and Director of publicly traded
molecular diagnostics company Sequenom, Inc., prior to that
company’s acquisition by Laboratory Corporation of America®
(LabCorp®) in September 2016. During his 18 year tenure at
Sequenom, he held positions of increasing responsibility including
Chief Scientific and Strategy Officer; Executive Vice President,
Research and Development; Chief Technology Officer; and Senior Vice
President of Research and Development. Dr. van den Boom has
co-authored more than 95 articles published in peer-reviewed
journals and is inventor on more than 80 patents and patent
applications. He received his Ph.D. in Biochemistry/Molecular
Biology from the University of Hamburg.
About CombiMatrix
Corporation
CombiMatrix Corporation provides best-in-class
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in pre-implantation genetic diagnostics and screening,
prenatal diagnosis, miscarriage analysis and pediatric
developmental disorders, offering DNA-based testing for the
detection of genetic abnormalities beyond what can be identified
through traditional methodologies. Our testing focuses on advanced
technologies, including single nucleotide polymorphism chromosomal
microarray analysis, next-generation sequencing, fluorescent in
situ hybridization and high resolution karyotyping.
Additional information about CombiMatrix is available at
www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," “approximates,”
"expects," "intends," "plans," "goal," "predicts," "believes,"
"seeks," "estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, statements regarding projected results of operations,
including projected cash flow-positive operating results,
management's future business, operational and strategic plans,
recruiting efforts and test menu expansion. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties referred
to above include, but are not limited to: our estimates of total
market sizes for the tests that we offer; our ability to grow
revenue and improve gross margin; delays in achieving cash
flow-positive operating results; the risk that test volumes and
reimbursements level off or decline; the risk that payors decide to
not cover our tests or to reduce the amounts they are willing to
pay for our tests; the risk that we will not be able to grow our
business as quickly as we need to; the inability to raise capital;
the loss of members of our sales force; our ability to successfully
expand the base of our customers, add to the menu of our diagnostic
tests, develop and introduce new tests and related reports, expand
and improve our current suite of diagnostic services, optimize the
reimbursements received for our molecular testing services, and
increase operating margins by improving overall productivity and
expanding sales volumes; our ability to successfully accelerate
sales, steadily increase the size of our customer rosters in all of
our genetic testing markets; our ability to attract and retain
a qualified sales force in wider geographies; our ability to ramp
production from our sales; rapid technological change in our
markets; changes in demand for our future services; legislative,
regulatory and competitive developments; general economic
conditions; and various other factors. Further information on
potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason, except as
required by law.
Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Contact:
LHA
Jody Cain
(310) 691-7100
jcain@lhai.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Sep 2023 to Sep 2024